Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study. Petrylak, D., Smith, D. C., Flaig, T. W., Zhang, J., Sridhar, S. S., Ruether, J. D., Plimack, E. R., Merchan, J. R., Quinn, D. I., Kilari, D., Srinivas, S., Baranda, J., Lang, J., Milowsky, M. I., Galsky, M. D., Spira, A. I., Gartner, E. M., Wu, C., Melhem-Bertrandt, A., Rosenberg, J. E. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.6_suppl.431
View details for Web of Science ID 000436179500425